Fevara plc (LSE:FVA) is in focus after its shares declined1.90% on 11 September 2026, making the specialist livestock-nutrition company one of the notable fallers in the latest market snapshot.
Applied Nutrition plc (LSE:APN) is one of the most closely watched UKGrowth Stockstoday after falling1.71% on 11 September 2026.
The trial also met key secondary endpoints, showing improvements in progression-free survival and objective response rate. It was conducted with Amgen, which developed Imdelltra, and randomised 563 patients one-to-one after they had completed induction treatment. That design places the combination in the maintenance phase, …
HeightsCapitalManagement, Inc., notifying through CVI Investments, Inc., raised its interest from 8.995% to 15.638%, or 94,431,274 voting rights, on 8 September. The reason given was anAcquisitionor disposal of voting rights. That makes it comfortably the largest disclosed holder on the register.
The group announced on 10 September 2026 that it had priced $700 million of 5.750% notes maturing on 11 September 2036, with closing expected the following day. Net proceeds are stated at $690,928,000. Two days earlier it had launched a cash tender offer for …
Until now, Shingrix has been supplied in Japan as two vials, a lyophilised antigen and a liquid adjuvant, which a healthcare professional must reconstitute before administration. The prefilled syringe removes that step. In a country where vaccination is delivered across a very large number …
Key HighlightsAstraZeneca (LSE:AZN) has rarely had a busier fortnight. On 4 September 2026 the US Food and Drug Administration grantedAccelerated Approvalto ETCAMAH (camizestrant), the oral oestrogen receptor degrader underpinning much of the group's breast cancer ambition.For the six months to 30 June 2026, totalRevenuereached …
Key HighlightsThe London healthcare cohort enters the autumn of 2026 against a macro background that is steadier than it was two years ago but still demands selectivity. Sterling has remained a meaningful variable for companies in this group, many of which earn a large …
Key HighlightsTo understand why this particular group of companies matters, it helps to step back and consider the shape of UK-listed healthcare in 2026. The sector is anchored at the top by two very large constituents of the FTSE 100 that pull in opposite …
Key HighlightsEntering the final weeks of September 2026, the backdrop for UK-listed healthcare and life-sciences companies is one of cautious normalisation rather than exuberance. The acute financing drought that weighed on small-cap biotechnology through the middle of the decade has eased from its worst, …